Volume 26, Number 3—March 2020
CME ACTIVITY - Research
Methicillin-Resistant Staphylococcus aureus Bloodstream Infections and Injection Drug Use, Tennessee, USA, 2015–2017
Table 1
Demographic and clinical characteristics of patients with methicillin-resistant Staphylococcus aureus bloodstream infections, by IDU status, Tennessee, USA, 2015–2017*
Characteristic | IDU status |
p value | Overall | |
---|---|---|---|---|
IDU | Non-IDU | |||
Total |
1,839 (24.1) |
5,807 (75.9) |
<0.001 |
7,646 (100) |
Onset year | <0.001 | |||
2015 | 375 (16.1) | 1,958 (83.9) | 2,333 (30.5) | |
2016 | 643 (25.0) | 1,924 (75.0) | 2,567 (33.6) | |
2017 |
821 (29.9) |
1,925 (70.1) |
2,746 (35.9) |
|
Onset type | <0.001 | |||
CO-ED | 1,156 (62.9) | 3,202 (55.1) | 4,358 (57.0) | |
CO-IP | 572 (31.1) | 1,911 (32.9) | 2,483 (32.5) | |
HO |
111 (6.0) |
694 (12.0) |
805 (10.5) |
|
Age range, y | <0.001 | |||
13–17 | 1 (0.1) | 24 (0.4) | 25 (0.3) | |
18–34 | 617 (33.6) | 387 (6.7) | 1,004 (13.1) | |
35–49 | 665 (36.2) | 912 (15.7) | 1,577 (20.63) | |
50–64 | 436 (23.7) | 1,789 (30.8) | 2,225 (29.1) | |
>65 | 120 (6.5) | 2,695 (46.4) | 2,815 (36.8) | |
Median (range, Q1–Q3) |
40 (31–51) |
63 (51–74) |
<0.001 |
|
Sex | <0.001 | |||
M | 910 (49.5) | 3,435 (59.2) | 4,345 (56.8) | |
F |
929 (50.5) |
2,372 (40.8) |
3,301 (43.2) |
|
Race | <0.001 | |||
White | 1,635 (88.9) | 4,511 (77.7) | 6,146 (80.4) | |
Black | 168 (9.1) | 1,193 (20.5) | 1,361 (17.8) | |
Other | 15 (0.8) | 56 (1.0) | 71 (0.9) | |
Unknown |
21 (1.1) |
47 (0.8) |
68 (0.9) |
|
Ethnicity | 0.820 | |||
Hispanic | 6 (0.3) | 22 (0.4) | 28 (0.4) | |
Non-Hispanic | 1,768 (96.1) | 5,563 (95.8) | 7,331 (95.9) | |
Unknown |
65 (3.5) |
222 (3.8) |
287 (3.8) |
|
Insurance | <0.001 | |||
Commercial | 109 (5.9) | 648 (11.2) | 757 (9.9) | |
Medicaid | 570 (31.0) | 655 (11.3) | 1,225 (16.0) | |
Medicare | 452 (24.6) | 3,688 (63.5) | 4,140 (54.2) | |
Self-pay/uninsured | 612 (33.3) | 476 (8.2) | 1,088 (14.2) | |
Other/unknown | 96 (5.2) | 340 (5.9) | 436 (5.7) |
*Values are no. (%) except as indicated. CO, community onset; ED, emergency department; HO, hospital onset; IDU, injection drug use; IP, inpatient.
Page created: February 12, 2020
Page updated: February 12, 2020
Page reviewed: February 12, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.